SyncAV

SyncAV Post-Market Trial

Objective

The SyncAV Post-Market Trial is a prospective, randomized, multi-center trial performed to determine if cardiac resynchronization therapy (CRT) devices programmed with SyncAV ON improve long-term CRT response compared to devices programmed with conventional CRT through evaluation of changes in left ventricular (LV) reverse remodeling.

  1. Inclusion

    • Scheduled to receive a new CRT implant or an upgrade (Abbott CRT device and Abbott Quadripolar LV lead) from an existing implantable cardioverter defibrillator/pacemaker implant with no more than 10% RV pacing at the last device interrogation, no prior LV lead placement, AND meet the following additional criteria:

      • Mild to severe heart failure despite optimal medical therapy for at least 3 months prior to signing consent. Optimal medical therapy is defined as maximal tolerated dose of beta-blockers and a therapeutic dose of angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, or aldosterone antagonist
      • LVEF ≤ 35% based on a prior standard of care echocardiogram
      • Left bundle branch block (LBBB) as documented on an ECG. Criteria for complete LBBB should include,
        • QRS duration ≥ 120 ms
        • QS or rS pattern in leads V1
        • mid-QRS notching or slurring in leads I, aVL, V5, and V6
        • Absence of Q-wave in leads V5 and V6 d. Intact AV conduction (PR interval ≤ 280 ms on surface ECG)
    • At least 18 years old, or of legal age and willing and capable to give informed consent specific to each country and national laws
    • Willing and able to comply with the prescribed follow-up tests and schedule of evaluations
  2. Exclusion

    • Recent myocardial infarction or unstable angina within 40 days prior to signing consent
    • Recent cardiac revascularization (angioplasty, stent or bypass graft) in the 4 weeks prior to signing consent or planned within 3 months following consent
    • Cerebrovascular accident or transient ischemic attack in the 3 months prior to signing consent
    • Any other therapeutic cardiovascular procedure (transcatheter aortic valve replacement, MitraClip, cardiac surgery, left atrial appendage closure, patent foramen ovale closure, or any ablation procedures) in the 3 months prior to signing consent
    • Permanent or persistent AF at the time of signing consent
    • Paroxysmal AF with at least one cardioversion within 60 days prior to signing consent
    • Prior CRT device implant
    • Prior His Bundle pacing implant or plan to have His Bundle pacing implant
    • Pregnant or breastfeeding at the time of signing consent
    • Incapacitated or unable to read or write
    • Undergone cardiac transplantation or have a classification of Status 1 for cardiac transplantation or consideration for transplantation during the study follow-up period
    • Life expectancy < 12 months due to any condition
    • Unavailable for at least 12 months of follow-up visits
    • Enrolled in or intend to participate in a clinical drug and/or device study during this clinical trial which could confound the results of this trial as determined by Abbott

Additional Info

Ethics ID: REB21-0273

ClinicalTrials.gov ID: NCT04100148

 

Sponsor: Abbott Medical Devices

 

PI: Dr. Glen Sumner

Phone: 403 944 5063

 

Admin: Jennifer McKeage

Phone: 403 210 6047

Email: jmckeage@ucalgary.ca

Updated Sept 19, 2023